Nivolumab Plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-017
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn53 - Structured Literature Review of the Prevalence of Microsatellite Instability High (Msi-H) and Deficient Mismatch Repair (Dmmr) Among Solid Tumors

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2020English

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Safety and Clinical Outcomes of Ipilimumab and Nivolumab Plus Concurrent Stereotactic Radiosurgery for Brain Metastases

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

P2.12-16 Significant Tumor Regression and Toxicity With Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Safety of Nivolumab Plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Hospitalization and Emergency Department Utilization in Patients With Advanced Melanoma Receiving Pembrolizumab vs. Ipilimumab Plus Nivolumab in US Academic Centers

Journal of Medical Economics
Health Policy
2019English

Intracranial Antitumor Responses of Nivolumab and Ipilimumab: A Pharmacodynamic and Pharmacokinetic Perspective, a Scoping Systematic Review

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy